 Secondary objectives: To evaluate between baseline and week 48: proportions of subjects: in virological failure confirmed VL 50 cpmL confirmed by a 2nd measure made between 2 to 4 weeks, with VL 50 cpmL and between 20 and 50 cpmL, emerging drug resistance if virological failure, CD4 cell count evolution, HIV DNA evolution, morphological and glucido-lipid parameters modifications, digestive treatment tolerance , adherence to treatment, overall cost of antiretroviral therapy, factors associated to virological failure including baseline and nadir CD4 cell count, darunavir plasma level, baseline HIV DNA viral load. 